The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2021 | BVD in heavily pretreated multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the use of bendamustine plus bortezomib and dexamethasone (BVD) in patients with heavily pretreated multiple myeloma. A retrospective analysis of real-world data from 81 patients with relapsed/refractory multiple myeloma who had received salvage therapy with BVD, demonstrated an overall response rate of 63%, with seven patients achieving a complete response and 18 patients achieving a very good partial response. 19 patients achieved stable disease. Dr Cerchione reports that BVD has shown potential as a good bridging therapy for second autologous or allogeneic stem cell transplantation and after failure of novel agents. This interview took place during the 2021 European Myeloma Network (EMN) congress.
